Literature DB >> 26380609

Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma.

Wayne Kuznar.   

Abstract

Entities:  

Year:  2015        PMID： 26380609      PMCID： PMC4570063     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  5 in total

1.  Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Authors:  Chengkuan Cai; Jingyuan Tang; Baixin Shen; Liucheng Ding; Yunpeng Shao; Zhengsen Chen; Yinchao Ma; Haoliang Xue; Zhongqing Wei
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

2.  Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.

Authors:  Daye Zhang; Yongxiang Zhang; Zeyuan Cai; Ying Tu; Zhansong Hu
Journal:  Exp Ther Med       Date:  2019-11-21       Impact factor: 2.447

Review 3.  Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.

Authors:  Mathias Alrø Fichtner Bendtsen; Daniela Grimm; Johann Bauer; Markus Wehland; Petra Wise; Nils E Magnusson; Manfred Infanger; Marcus Krüger
Journal:  Int J Mol Sci       Date:  2017-08-10       Impact factor: 5.923

4.  Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress.

Authors:  Guoyu Wang; Juhua Zhuang; Jing Ni; Ying Ye; Saifei He; Wei Xia
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

5.  Therapeutic effects of lenvatinib in combination with rAd-p53 for the treatment of non-small cell lung cancer.

Authors:  Renzhi Yu; Minghuan Wang; Xiuli Zhu; Zhe Sun; Aiying Jiang; Huixin Yao
Journal:  Oncol Lett       Date:  2018-09-11       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.